News Focus
News Focus
icon url

turtlepower

09/30/12 11:19 PM

#149703 RE: mcbio #149701

The MOS for the erlotinib control arm is assumed to be 7 months. So unless they have sicker patients in the trial the alternative has to be bearish if the interim is much earlier than expected.
icon url

jq1234

09/30/12 11:19 PM

#149704 RE: mcbio #149701

I agree. I don't pay much attention to projected timeline unless it is way way off mark.